Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies
Authors
Keywords
-
Journal
Frontiers in Cardiovascular Medicine
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-11-19
DOI
10.3389/fcvm.2021.758010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review
- (2021) Qinchao Wu et al. CARDIOVASCULAR DRUGS AND THERAPY
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib
- (2020) Alice Barbarin et al. Scientific Reports
- Risk of QTc Prolongation Among Cancer Patients Treated with Tyrosine Kinase Inhibitors
- (2020) Anan A. Abu Rmilah et al. INTERNATIONAL JOURNAL OF CANCER
- Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
- (2020) Anand Prakash Singh et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
- (2020) Santa Cirmi et al. Cancers
- Identification of anticancer drugs associated with atrial fibrillation - analysis of the WHO pharmacovigilance database
- (2020) Joachim Alexandre et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK
- (2020) Ling Xiao et al. CIRCULATION
- Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
- (2020) Robin Foà et al. NEW ENGLAND JOURNAL OF MEDICINE
- Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors
- (2020) Melinda D. Wu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Management of treatment-related toxicities in advanced medullary thyroid cancer
- (2019) Venessa H.M. Tsang CURRENT OPINION IN ONCOLOGY
- Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared to Cytotoxic Chemotherapy
- (2019) Michael G. Fradley et al. AMERICAN JOURNAL OF CARDIOLOGY
- Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
- (2019) Lorenza Rimassa et al. CANCER TREATMENT REVIEWS
- Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium
- (2019) Le Jiang et al. HEART RHYTHM
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- (2019) Soo Young Kim et al. Frontiers in Endocrinology
- Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2019) Yunhang Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies
- (2018) Jan de Jong et al. LEUKEMIA & LYMPHOMA
- Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor
- (2018) Xianbin Tian et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
- (2018) Maher Chaar et al. OncoTargets and Therapy
- Nilotinib in the treatment of chronic myeloid leukemia
- (2018) Tomasz Sacha et al. Future Oncology
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Cardiovascular Complications of Cancer Therapy
- (2017) Hui-Ming Chang et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular Complications of Cancer Therapy
- (2017) Hui-Ming Chang et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
- (2017) Arun Sharma et al. Science Translational Medicine
- Acquired long QT syndrome and phosphoinositide 3-kinase
- (2017) Ira S. Cohen et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Pharmacology and pharmacokinetics of imatinib in pediatric patients
- (2017) Meinolf Suttorp et al. Expert Review of Clinical Pharmacology
- Ponatinib: A Review of Efficacy and Safety
- (2017) Fulvio Massaro et al. CURRENT CANCER DRUG TARGETS
- Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
- (2016) Neil P. Shah et al. AMERICAN JOURNAL OF HEMATOLOGY
- Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion
- (2016) Massimo Breccia et al. ANNALS OF HEMATOLOGY
- Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
- (2016) S.-H. Lee et al. ANNALS OF ONCOLOGY
- The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
- (2016) Darryl P. Leong et al. BLOOD
- The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
- (2016) Sarah E.M. Herman et al. CLINICAL CANCER RESEARCH
- Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling
- (2016) L de Zwart et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
- (2016) Peng Wu et al. DRUG DISCOVERY TODAY
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
- (2016) Jose Luis Zamorano et al. EUROPEAN HEART JOURNAL
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
- (2016) Jeffrey H Lipton et al. LANCET ONCOLOGY
- Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit
- (2015) Rashmi R. Shah et al. DRUG SAFETY
- Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam
- (2015) Hefei Zhang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
- (2014) S. E. M. Herman et al. BLOOD
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
- (2014) P Ghatalia et al. BRITISH JOURNAL OF CANCER
- Ibrutinib: First Global Approval
- (2014) Fiona Cameron et al. DRUGS
- Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
- (2014) J. M. Drake et al. MOLECULAR AND CELLULAR BIOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
- (2013) Daryl Sonnichsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia
- (2013) Takashi Shibata et al. International Journal of Clinical Oncology
- Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
- (2013) Narayana I. Narasimhan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
- (2013) S Cheng et al. LEUKEMIA
- Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
- (2013) Paul Martin et al. Drugs in research & development
- Ariad Suspends Ponatinib Sales
- (2013) Cancer Discovery
- Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary
- (2012) K. Thornton et al. CLINICAL CANCER RESEARCH
- Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
- (2012) Francis J. Giles et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical cardiac safety profile of nilotinib
- (2012) T. D. Kim et al. HAEMATOLOGICA
- A tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition
- (2012) Wenyue Hu et al. JOURNAL OF APPLIED TOXICOLOGY
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- hERG K+ Channels: Structure, Function, and Clinical Significance
- (2012) Jamie I. Vandenberg et al. PHYSIOLOGICAL REVIEWS
- Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome
- (2012) Z. Lu et al. Science Translational Medicine
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2011) R. Foa et al. BLOOD
- Nilotinib
- (2011) Karly P. Garnock-Jones DRUGS
- Vandetanib
- (2011) Helen Commander et al. DRUGS
- Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase
- (2011) Richard A. Larson et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
- (2010) Paul W. Manley et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
- (2010) A. Haouala et al. BLOOD
- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors
- (2010) Faye M. Johnson et al. CANCER
- Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis
- (2010) Tao Chen et al. CANCER TREATMENT REVIEWS
- Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment
- (2010) Angelika Weil et al. CLINICAL PHARMACOKINETICS
- Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants
- (2010) Chiaki Tanaka et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting non-malignant disorders with tyrosine kinase inhibitors
- (2010) Friedrich Grimminger et al. NATURE REVIEWS DRUG DISCOVERY
- QTc shortening with a new investigational cancer drug: A brief case study
- (2010) Herbert M. Himmel et al. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started